Michael Krathen, MD
Dermatology · Natick, MANPI 1932376050
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,230 of the $1,471 with a category attached, or 83.6%. 21 manufacturers reported payments, led by AbbVie at 24.1% of the total. 2025 is the largest year on record at $547, 3.0 times the $184 reported in 2019.
Across 58 payments — averaging $25.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$355
- Johnson & Johnson$207
- UCB, Inc.$128
- Lilly USA, LLC$128
- Regeneron Healthcare Solutions, Inc.$127
- E.r. Squibb & Sons, L.L.C.$82
- plus $445 from 15 others
Across 3 payments — averaging $8331.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$16K
- Incyte Corporation$9K
What the payments were for
- Food & beverage$1,23084%
- Education$24116%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $355 |
| Johnson & Johnson | 5 | $207 |
| UCB, Inc. | 6 | $128 |
| Lilly USA, LLC | 6 | $128 |
| Regeneron Healthcare Solutions, Inc. | 2 | $127 |
| E.r. Squibb & Sons, L.L.C. | 3 | $82 |
| Sun Pharmaceutical Industries Inc. | 3 | $65 |
| Novartis | 4 | $63 |
| Galderma Laboratories, L.p. | 3 | $52 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $32 |
| Boehringer Ingelheim | 1 | $30 |
| Dermavant Sciences, Inc. | 1 | $26 |
| LEO Pharma Inc. | 1 | $25 |
| Incyte Corporation | 1 | $24 |
| Botanix SB Inc | 1 | $23 |
| Biofrontera Inc. | 1 | $21 |
| Sanofi | 1 | $21 |
| Arcutis Biotherapeutics, Inc. | 1 | $19 |
| Convatec Inc. | 1 | $17 |
| Pfizer | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $14 |
How this compares
$1,471 in reported general payments places this provider in the 55th percentile of 552 dermatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 36 | $198,947 |
| Clobetasol Propionate | 43 | $3,370 |
| Mycophenolate Mofetil | 12 | $3,198 |
| Fluorouracil | 44 | $2,004 |
| Metronidazole | 45 | $1,748 |
| Tacrolimus | 12 | $1,720 |
| Finasteride | 121 | $1,560 |
| Minoxidil | 105 | $1,419 |
| Triamcinolone Acetonide | 105 | $1,314 |
| Mometasone Furoate | 53 | $1,137 |
| Betamethasone Dipropionate | 30 | $986 |
| Gentamicin Sulfate | 21 | $817 |
| Imiquimod | 22 | $647 |
| Clindamycin Phosphate | 26 | $603 |
| Fluocinonide | 12 | $457 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Natick
- John HarrisWorcester$15M
- Ethan LernerCharlestown$1.7M
- Michael KaminerChestnut Hill$1.1M
- Jeffrey SobellChestnut Hill$986K
- Erik DominguesFall River$736K
- Alexandra KimballBoston$680K
- Arash MostaghimiBoston$591K
- David GreensteinBeverly$540K
- Brian HiblerBoston$498K
- Maryanne SennaBoston$430K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.